Pathos AI raises $237m to scale its drug-development platform and cancer pipeline
Pathos AI has closed a $237 million Series E led by Bristol Myers Squibb, valuing the clinical-stage company at about $3 billion. It plans to use the funding to expand its AI...
Started by Watch Desk- Replies
- 0